Skeletal consequences of thiazolidinedione therapy
Author:
- 28 September 2007
- journal article
- review article
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (2) , 129-137
Abstract
Thiazolidinediones (TZDs) are agonists of the peroxisome proliferator-activated receptor gamma (PPARγ) nuclear transcription factor. Two members of this drug class, rosiglitazone and pioglitazone, are commonly used in the management of type II diabetes mellitus, and play emerging roles in the treatment of other clinical conditions characterized by insulin resistance. Over the past decade, a consistent body of in vitro and animal studies has demonstrated that PPARγ signaling regulates the fate of pluripotent mesenchymal cells, favoring adipogenesis over osteoblastogenesis. Treatment of rodents with TZDs decreases bone formation and bone mass. Until recently, there were no bone-related data available from studies of TZDs in humans. In the past year, however, several clinical studies have reported adverse skeletal actions of TZDs in humans. Collectively, these investigations have demonstrated that the TZDs currently in clinical use decrease bone formation and accelerate bone loss in healthy and insulin-resistant individuals, and increase the risk of fractures in the appendicular skeleton in women with type II diabetes mellitus. These observations should prompt clinicians to evaluate fracture risk in patients for whom TZD therapy is being considered, and initiate skeletal protection in at-risk individuals.Keywords
This publication has 76 references indexed in Scilit:
- Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged BoneEndocrinology, 2007
- Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in VivoEndocrinology, 2007
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsThe Journal of Clinical Endocrinology & Metabolism, 2006
- Regulation of osteoclast function and bone mass by RAGEJournal of Experimental Medicine, 2006
- Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fatBone, 2006
- Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black AdultsArchives of internal medicine (1960), 2005
- Distinct effects of PPARγ insufficiency on bone marrow cells, osteoblasts, and osteoclastic cellsJournal of Bone and Mineral Metabolism, 2005
- Adiponectin increases bone mass by suppressing osteoclast and activating osteoblastBiochemical and Biophysical Research Communications, 2005
- Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patientsJournal of Bone and Mineral Metabolism, 2003
- Activation of Peroxisome Proliferator-activated Receptor-γ Pathway Inhibits Osteoclast DifferentiationJournal of Biological Chemistry, 2000